Apr 20, 2015 7:00am EDT Can-Fite Applies for Orphan Drug Designation in Europe for CF102 in the Treatment of Liver Cancer
Mar 30, 2015 9:11am EDT Can-Fite Reports Top-Line Results from Phase II/III Trial for CF101 in Treatment of Psoriasis
Mar 23, 2015 7:00am EDT Can-Fite Signs Multi-Million Dollar Distribution Agreement for CF101 in Canada with Cipher Pharmaceuticals
Mar 18, 2015 7:00am EDT Can-Fite Completes Development of Commercial Biomarker Test to Predict Patients' Response to Company Drugs
Jan 27, 2015 7:00am EST Can-Fite's CF602 Demonstrates Efficacy in Treatment of Sexual Dysfunction in Preclinical Studies
Jan 06, 2015 7:15am EST Can-Fite Announces Upcoming 2015 Clinical Milestones for its Pipeline of Drugs in 4 Indications
Dec 30, 2014 7:00am EST Can-Fite Completes the Design of the Rheumatoid Arthritis Phase III Study of Its Lead Drug Candidate CF101
